Gut Microbe Molecule 7-KDCA Shields Diabetic Muscles by Blocking NLRP1-Ferroptosis Cell Death

A molecule manufactured by gut bacteria may hold the key to protecting the muscles of people with type 2 diabetes. In a study published in Cell Death Discovery, researchers report that 7-ketodeoxycholic acid, or 7-KDCA, a secondary bile acid produced by intestinal microbes, drops sharply in diabetic mice and in diabetic patients with sarcopenia, and that restoring the molecule reverses muscle wasting in diabetic animals. The work, led by Qing-Bo Lu, Chen-Yang Zhao, Le Yang and Yuan Zhang working with senior authors Hai-Jian Sun and Xue-Xue Zhu at Jiangnan University and collaborating institutions, traces the protective effect to a precise molecular switch: interference with a crosstalk between the NLRP1 inflammasome and ferroptosis, an iron-dependent form of cell death, inside muscle fibers.

Sarcopenia, the progressive loss of skeletal muscle mass and strength, becomes especially dangerous when it overlaps with type 2 diabetes, a combination that is emerging as a major clinical challenge in aging populations. Diabetic sarcopenia accelerates frailty, impairs mobility and reduces quality of life, yet treatment options remain scarce. The research team approached the problem through metabolomics, the large-scale study of small molecules in biological fluids, on the hypothesis that gut microbial metabolites might act as circulating signals that shape muscle health. Bile acids, best known for digesting fats, have increasingly been recognized as signaling molecules, and the new study adds muscle biology to their growing list of targets.

Using both untargeted and targeted metabolomic profiling, the investigators found that fecal and serum levels of 7-KDCA were significantly downregulated in mice with type 2 diabetes. Crucially, the same depletion appeared in human patients: diabetic individuals with sarcopenia also carried reduced 7-KDCA, and within the enrolled patient cohort the molecule’s abundance correlated positively with the skeletal muscle index and skeletal muscle density, two clinical imaging-based measures of muscle quantity and quality. That parallel finding in rodents and humans gave the team a compelling reason to test whether the missing metabolite was a bystander or a driver of the disease.

The answer came from supplementation experiments. When diabetic mice received 7-KDCA, the animals showed ameliorated glucose intolerance, attenuated muscle atrophy, restored muscle function and enhanced exercise capacity. The treatment also improved intestinal permeability, suggesting the molecule helps maintain the gut barrier that diabetes tends to erode. In cultured C2C12 myotubes, the standard laboratory model of differentiated skeletal muscle cells, 7-KDCA promoted cell differentiation, stimulated protein synthesis and boosted glucose uptake, the very processes that falter when diabetic muscle wastes away.

But where did the missing 7-KDCA come from in the first place? By sequencing the gut microbial communities of the experimental animals and patients, the team identified two bacterial species whose abundance collapsed in diabetes: Bifidobacterium pseudolongum and Lactobacillus murinus. These microbes are key producers of 7-KDCA in the intestine. When the researchers colonized the guts of diabetic mice with the two species, the animals experienced benefits that mirrored direct 7-KDCA administration, including preserved muscle mass and function. This microbial transfer experiment suggests a potential probiotic route to the same therapeutic endpoint, raising the prospect that engineered or selected bacterial cocktails could one day complement conventional diabetes care.

The deepest technical contribution of the study lies in its mechanistic dissection of what 7-KDCA actually does inside muscle cells. RNA sequencing of treated myotubes, combined with targeted biochemical assays, pointed to the NLRP1 inflammasome, an innate immune sensor that can ignite inflammatory death programs. According to the authors’ model, 7-KDCA inhibits NLRP1 inflammasome activation, and this suppression in turn blocks ferroptosis, a form of regulated cell death driven by lipid peroxidation and iron accumulation that has been implicated in degenerative muscle loss. In other words, the metabolite interrupts a pathological dialogue in which inflammatory signaling and ferroptotic death reinforce one another in muscle fibers.

The team tested that model causally rather than merely observing correlations. Muramyl dipeptide, a well-characterized potent agonist of NLRP1, reversed the benefits of 7-KDCA in myotubes, as did Erastin, a classic inducer of ferroptosis that acts by depleting cellular antioxidant defenses. If either the inflammasome was reactivated or ferroptosis was forced back on, the protective effects of the bile acid largely disappeared. This reciprocal loss-of-function evidence supports the idea that the 7-KDCA/NLRP1/ferroptosis axis is not an incidental correlate but a functional pathway that can be manipulated therapeutically, and it explains why the molecule’s effects span both metabolism and muscle integrity.

The implications extend beyond diabetes. Because ferroptosis and inflammasome activation feature prominently in many age-related degenerative conditions, a gut-derived metabolite that tunes both processes through a single axis could inform strategies for a range of metabolic and neuromuscular disorders. The authors argue that targeting the 7-KDCA/NLRP1/ferroptosis pathway offers a promising therapeutic approach for metabolic disease complicated by sarcopenia, whether through direct administration of the bile acid, through probiotic supplementation with its bacterial producers, or through interventions that encourage endogenous production by reshaping the gut ecosystem.

Substantial caveats remain before such applications reach the clinic. The mouse findings came from induced diabetic models whose muscle pathology may not fully recapitulate the slowly evolving sarcopenia of elderly human patients, and the human data, while showing a clear association between 7-KDCA and muscle parameters, demonstrate correlation rather than causation. Dosing, safety, pharmacokinetics and long-term effects of elevating a secondary bile acid systemically all require dedicated study, and the microbiome of individual patients may respond differently to colonization attempts. Still, the study exemplifies a broader shift in biomedical research: treating the gut microbiota not as background noise but as a pharmaceutically productive organ whose chemical output can be measured, manipulated and, increasingly, prescribed.

For the millions of people living with type 2 diabetes who face progressive muscle loss with few effective remedies, the study offers something concrete: a defined molecule, two defined bacterial species and a defined intracellular target, all connected in one experimentally validated chain from gut to muscle fiber. If subsequent trials confirm the mechanism in humans, the humble bile acid chemistry of the intestine could become an unexpected ally in the fight against one of diabetes’ most disabling complications, turning microbial metabolism into a genuine therapeutic frontier for muscle medicine.

Subject of Research: Gut microbiota-derived bile acid 7-KDCA and its protection against diabetic sarcopenia via the NLRP1-ferroptosis pathway

Article Title: Gut microbiota-derived 7-KDCA protects against diabetic sarcopenia by interrupting the NLRP1-ferroptosis crosstalk in myotubes

Article References: Gut microbiota-derived 7-KDCA protects against diabetic sarcopenia by interrupting the NLRP1-ferroptosis crosstalk in myotubes. (n.d.). https://doi.org/10.1038/s41420-026-03331-4

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03331-4

Keywords: gut microbiota, 7-KDCA, bile acids, diabetic sarcopenia, type 2 diabetes, NLRP1 inflammasome, ferroptosis, myotubes, Bifidobacterium pseudolongum, Lactobacillus murinus, metabolomics, muscle atrophy